deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT02947165

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies

Sponsor: Novartis Pharmaceuticals

Conditions Breast Cancer Colorectal Cancer Hepatocellular Cancer Lung Cancer Pancreatic Cancer Renal Cancer
Interventions NIS793 PDR001
Updated 23 times since 2017 Last updated: Jan 28, 2022 Started: Apr 25, 2017 Primary completion: Jun 18, 2021 Completion: Jun 18, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Breast Cancer and Colorectal Cancer, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 23 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Aug 2019 · 8 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Jul 2024 · 29 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

23 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Feb 2022 — Jul 2024 [monthly]

    Completed PHASE1

  5. Sep 2021 — Feb 2022 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 18 earlier versions

  1. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  2. May 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  6. Sep 2020 — Dec 2020 [monthly]

    Recruiting PHASE1

  7. Feb 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  8. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  9. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  10. Dec 2018 — Aug 2019 [monthly]

    Recruiting PHASE1

  11. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  12. Jul 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  13. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  14. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  15. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

  16. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  17. Feb 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE1

  18. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Hong Kong, Hong Kong , Kashiwa, Japan , Milan, Italy , Nashville, United States , Rozzano, Italy , Salt Lake City, United States , Salzburg, Austria , Sankt Gallen, Switzerland , Taipei, Taiwan , Toronto, Canada and 2 more locations